<DOC>
	<DOCNO>NCT01944618</DOCNO>
	<brief_summary>The study purpose assess adverse event patient Type 2 diabetes newly prescribe Forxiga management glycemic control</brief_summary>
	<brief_title>forREAL : FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM ( PEMP )</brief_title>
	<detailed_description>Observational Model : Other : A post-marketing evaluation safety Forxiga observational prescription adverse event monitoring program ( registry-based monitoring program ) warrant assess real-world incidence adverse event routine clinical practice</detailed_description>
	<criteria>Patients Type 2 Diabetes : Prescribed Forxiga glycaemic management AND Who ability provide inform consent Patients use Forxiga contraindicate : Patients Type 1 Diabetes Patients moderate severe renal impairment [ Creatinine clearance ( CrCl ) &lt; 60 mL/min estimate glomerular filtration rate ( eGFR ) &lt; 60mL/min/1.73mÂ² ] Additional exclusion criterion : Age &gt; 75 year Concomitant use loop diuretic pioglitazone Patients currently another SGLT2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>